Barclays on IBM (IBM); Leading the 'Industrialization' of Large-Cap Tech Stocks
Get Alerts IBM Hot Sheet
Price: $190.96 +0.08%
Rating Summary:
12 Buy, 23 Hold, 4 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
12 Buy, 23 Hold, 4 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on IBM (NYSE: IBM) price target of $217.00.
Analyst, Ben A. Reitzes, feels that IBM has started a new 'Industrialization' trend in technology and is the current leader in this new space. Reitzes compares IBM to several industrial companies, specifically multiple expansion, and is currently well ahead of HP (NYSE: HPQ), Dell (Nasdaq: DELL) and Microsoft (Nasdaq: MSFT). Currently, IT hardware stocks have an average multiple around 10x, and industrial stocks are closer to 16.5x.
Reitzes and other Barclays analysts will comment further on the Company and the stock's development after IBM analyst on May 9th.
For an analyst ratings summary and ratings history on IBM click here. For more ratings news on IBM click here.
Shares of IBM closed at $204.99 yesterday.
Analyst, Ben A. Reitzes, feels that IBM has started a new 'Industrialization' trend in technology and is the current leader in this new space. Reitzes compares IBM to several industrial companies, specifically multiple expansion, and is currently well ahead of HP (NYSE: HPQ), Dell (Nasdaq: DELL) and Microsoft (Nasdaq: MSFT). Currently, IT hardware stocks have an average multiple around 10x, and industrial stocks are closer to 16.5x.
Reitzes and other Barclays analysts will comment further on the Company and the stock's development after IBM analyst on May 9th.
For an analyst ratings summary and ratings history on IBM click here. For more ratings news on IBM click here.
Shares of IBM closed at $204.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Safran SA (SAF:FP) (SAFRY) PT Raised to EUR211 at Citi, 'remain positive on the aftermarket'
- 4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
- Vertiv Holdings Co. (VRT) PT Raised to $94 at Wolfe Research, 'price targets could continue to trend towards bull case scenarios'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!